Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults with Chronic Hepatitis B
收藏DataCite Commons2024-12-04 更新2025-04-16 收录
下载链接：
https://repository.niddk.nih.gov/studies/hbrn-immune-tolerant-a
下载链接
链接失效反馈官方服务：
资源简介：
The Hepatitis B Research Network Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults with Chronic Hepatitis B (HBRN Immune Tolerant A) study sought to determine the efficacy of treatment with 8 weeks of entecavir followed by 40 weeks of both entecavir and peginterferon in the treatment of chronic hepatitis B in hepatitis B “e” antigen (HBeAg) positive adults who were in the immune tolerant phase. Additionally, the study evaluated the safety and sustained responses after treatment with entecavir and peginterferon alfa-2a in the treatment of chronic hepatitis B in HBeAg positive adults in the immune tolerant phase.
提供机构：
NIDDK Central Repository
创建时间：
2024-12-03
